Jonathan Gardner

Charlottesville

Senior reporter, BioPharma Dive. Father of 1, husband of 1, son of 2, brother of 2, uncle of 7. Opinions are mine. RTs are not endorsements. Darn good runner.

Featured in: Favicon

biopharmadive.com Favicon

healthcaredive.com Favicon

newsbreak.com Favicon

supplychaindive.com Favicon

k12dive.com Favicon

evaluate.com Favicon

medtechdive.com Favicon

cfodive.com Favicon

greenbeltnewsreview.com Favicon

legaldive.com + 6 more

Articles

5 questions on Trump’s plan to lower US drug prices

2 days ago | biopharmadive.com | Jonathan Gardner

President Donald Trump’s declaration Monday that the Department of Health and Human Services will pursue a plan to “equalize” drug prices with other countries both seeks to fulfill a campaign promise and fits with the “America first” theme of his second term. The path forward is uncertain, however.
Trump revives ‘most favored nation’ plan in effort to cut US drug prices

3 days ago | biopharmadive.com | Jonathan Gardner |Ned Pagliarulo

The Trump administration is resurrecting a controversial policy that aims to tamp down some pharmaceutical costs in the U.S. by linking them to prices paid abroad, delivering another jolt to an industry it has already targeted for tariffs.
Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.

1 week ago | biopharmadive.com | Jonathan Gardner

To hear Vinay Prasad tell it, U.S. healthcare is too ready to intervene unnecessarily, use prescription drugs without sufficient evidence of their benefit and put patients at risk of side effects or other negative outcomes. The Food and Drug Administration has, in Prasad’s opinion, leaned too heavily on measures of effectiveness for cancer medicines that don’t help people live meaningfully longer, and cost too much for the benefit they deliver.
Vinay Prasad, a physician and FDA critic, to lead agency center overseeing vaccines

1 week ago | biopharmadive.com | Ben Fidler |Jonathan Gardner

Vinay Prasad, a prolific academic and longtime critic of U.S. drug policies, was named Wednesday as the new leader of a main Food and Drug Administration office. FDA Commissioner Martin Makary announced Prasad’s appointment as the new director of the Center for Biologics Evaluation and Research, which oversees review of vaccines, blood products and some genetic medicines.
Trump orders FDA to help speed building of new drug factories

1 week ago | biopharmadive.com | Jonathan Gardner

Dive Brief:The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to speed their completion and boost domestic supply, under an executive order signed Monday by President Donald Trump.
Amgen’s Stelara biosimilar gets off to fast start

1 week ago | biopharmadive.com | Jonathan Gardner

Dive Brief:Amgen on Thursday said its just-launched biosimilar of Johnson & Johnson’s autoimmune drug Stelara recorded $150 million in sales in the first quarter, spotlighting rising revenue from the biotech’s portfolio of copycat biologics. During the company’s first quarter earnings call, commercial chief Murdo Gordon said Amgen’s biosimilar products recorded $735 million in sales, roughly 9% of the company’s revenues.
Pharma downplays tariff threat, even as risks remains unclear

2 weeks ago | biopharmadive.com | Ned Pagliarulo |Jonathan Gardner

The threat of tariffs on pharmaceuticals imported to the U.S. hasn’t yet pushed drugmakers off course, with many of the largest companies indicating they expect to be able to absorb any impact in the short term. Speaking on earnings calls in recent weeks, pharma executives have, for the most part, told investors their supply chains are flexible enough to mitigate the effects of new levies — for this year, at least.
Novo partners with telehealth companies in move to expand Wegovy market

2 weeks ago | biopharmadive.com | Jonathan Gardner

Novo Nordisk will work with some of the telehealth companies that sold knock-off versions of obesity drugs like its popular medicine Wegovy, announcing Tuesday deals with Hims & Hers, LifeMD and Ro to sell branded Wegovy distributed through the Danish drugmaker’s direct-to-consumer pharmacy.
Novo partners with telehealth companies in move to expand Wegovy market

2 weeks ago | finance.yahoo.com | Jonathan Gardner

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Jonathan Gardner Tue, Apr 29, 2025, 6:10 AM 2 min read In This Article: This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Merck takes $200M tariff hit, trimming its gross profits

3 weeks ago | biopharmadive.com | Jonathan Gardner

Dive Brief:Merck & Co. “absorbed” $200 million in addition expenses related to U.S. and overseas tariffs in the first quarter of 2025, increasing its cost of selling products and trimming a half percent from its gross profits, the company said Thursday. The company doesn’t intend to use price hikes as a “lever” to offset tariff costs, CEO Rob Davis said on a conference call.